Encephalitogenic myelin peptides specific T-cell therapy (multiple sclerosis), Sheba Medical Center

N/A

Report date: 2023/02/18 22:36:44

Base Information

Drug NameEncephalitogenic myelin peptides specific T-cell therapy (multiple sclerosis), Sheba Medical Center
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy
Mechanisms of ActionT lymphocyte replacements
TargetsNot applicable
Therapy Area/IndicationsMultiple Sclerosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesChaim Sheba Medical Center At Tel Hashomer
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesChaim Sheba Medical Center At Tel Hashomer
Active IndicationsN/A
Inactive IndicationsMultiple Sclerosis

Other Information

ATC CodeN/A
Related LinksN/A